- Home
- PPTA vs YMAB Comparison
PPTA vs YMAB Comparison
Compare PPTA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPTA
- YMAB
- Stock Information
- Founded
- PPTA 2011
- YMAB 2015
- Country
- PPTA United States
- YMAB United States
- Employees
- PPTA N/A
- YMAB N/A
- Industry
- PPTA Precious Metals
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PPTA Basic Materials
- YMAB Health Care
- Exchange
- PPTA Nasdaq
- YMAB Nasdaq
- Market Cap
- PPTA 573.6M
- YMAB 631.1M
- IPO Year
- PPTA N/A
- YMAB 2018
- Fundamental
- Price
- PPTA $10.60
- YMAB $11.14
- Analyst Decision
- PPTA Strong Buy
- YMAB Strong Buy
- Analyst Count
- PPTA 2
- YMAB 8
- Target Price
- PPTA $18.50
- YMAB $21.38
- AVG Volume (30 Days)
- PPTA 369.3K
- YMAB 268.9K
- Earning Date
- PPTA 11-13-2024
- YMAB 11-08-2024
- Dividend Yield
- PPTA N/A
- YMAB N/A
- EPS Growth
- PPTA N/A
- YMAB N/A
- EPS
- PPTA N/A
- YMAB N/A
- Revenue
- PPTA N/A
- YMAB $84,553,000.00
- Revenue This Year
- PPTA N/A
- YMAB $10.24
- Revenue Next Year
- PPTA N/A
- YMAB $20.21
- P/E Ratio
- PPTA N/A
- YMAB N/A
- Revenue Growth
- PPTA N/A
- YMAB N/A
- 52 Week Low
- PPTA $2.69
- YMAB $5.17
- 52 Week High
- PPTA $10.75
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- PPTA 59.98
- YMAB 25.01
- Support Level
- PPTA $8.67
- YMAB $12.47
- Resistance Level
- PPTA $9.64
- YMAB $15.69
- Average True Range (ATR)
- PPTA 0.69
- YMAB 0.97
- MACD
- PPTA -0.06
- YMAB -0.46
- Stochastic Oscillator
- PPTA 93.02
- YMAB 9.88
About PPTA Perpetua Resources Corp.
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.